The primary endpoint was improvement in Hb levels before and after treatment, and Cancer Fatigue Scale (CFS) and Visual Analogue Scale for Anxiety (VAS-A) scores between groups. The gene discussed is GSTM1; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.